Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients

Rashid Sayyid, Urologic Oncology Clinical Fellow at University of Toronto, shared a post on X:

“RW study of LuPSMA in VISION-eligible mCRPC patients from expanded access program (UCLA, UCSF, Tulane, Johns Hopkins; n=117) compared to VISION phase 3 results.

• RW patients more likely to have received >1 ARPI (70% versus 46%), have worse PS, and have LN disease
• Similar OS (15.1) and PSA50 (42%)
• Increased incidence of Gr3+ lymphopenia in RW (34% versus 8%)

Results support use of LuPSMA in RW setting.”

Source: Rashid Sayyid/X